Skip to main content Skip to navigation Skip to search

Media

Press releases

2025

april 10, 2025 - Regulatory press release

Enzymatica publishes annual report for 2024

april 2, 2025 - Regulatory press release

Notice of Annual General Meeting 2025 in Enzymatica AB (publ)

mars 6, 2025 - Non-regulatory press release

Replay Link to Digital Press Briefing – March 5, 2025

februari 28, 2025 - Non-regulatory press release

Invitation to Press Briefing – 5 March 2025

februari 28, 2025 - Regulatory press release

New independent studies show that ColdZyme addresses the root cause of respiratory infections, reducing sick days and symptoms

februari 18, 2025 - Regulatory press release

Year-end report 2024: Strong performance in core markets – preparing for international growth

januari 9, 2025 - Non-regulatory press release

Enzymatica focuses on growth with new recruitment – Anna Söderlund joins as Senior Director Marketing & Sales

2024

november 7, 2024 - Regulatory press release

Interim report Q3/2024: Focus on developing existing and new markets

september 12, 2024 - Regulatory press release

Enzymatica announces outcome of new rights issue

september 9, 2024 - Regulatory press release

Enzymatica publishes supplementary prospectus

september 5, 2024 - Regulatory press release

Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load

augusti 26, 2024 - Regulatory press release

Publication of prospectus regarding Enzymatica’s rights issue

augusti 16, 2024 - Regulatory press release

Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days.

augusti 6, 2024 - Regulatory press release

Bulletin from the extraordinary general meeting of Enzymatica AB (publ) on 6 August 2024

juli 18, 2024 - Regulatory press release

Interim report Q2/2024: Enzymatica builds momentum for expansion

juli 18, 2024 - Regulatory press release

Enzymatica's Board of Directors updates the financial targets

juli 18, 2024 - Regulatory press release

Notice of Extraordinary General Meeting in Enzymatica AB (publ)

juli 18, 2024 - Regulatory press release

Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million

juni 13, 2024 - Regulatory press release

Interim results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days

maj 7, 2024 - Regulatory press release

Bulletin from annual general meeting of Enzymatica AB (publ) on May 7, 2024